EvlaBio AG
Addressing Unmet Needs in the Cardiorenal Space
EvlaBio is a biotech company, focused on the development of a therapy addressing a high unmet medical need in the cardiorenal space.
Specifically, we are addressing Left Ventricular Hypertrophy (LVH) in the setting of chronic kidney disease, which affects millions of patients and for which there are limited treatment options.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
07.07.2025
EvlaBio secures €21 million in seed funding (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
EvlaBio AG
Addressing Unmet Needs in the Cardiorenal Space
Website:
evlabio.com/
Headquarter:
Zürich
Foundation Date:
February 2022
Technology:
- Biotech